← All indications
Nasopharyngeal Neoplasms
Tumors or cancer of the NASOPHARYNX.
Subtype terms (1)
More specific conditions that are subtypes of Nasopharyngeal Neoplasms in the MeSH hierarchy.
- Nasopharyngeal Carcinoma
209 drugs (87 approved, 122 experimental)
Drugs by status
Approved for this indication (1)
Phase 3 trials (17)
Phase 2 trials (45)
- 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
- azacitidine
- anlotinib
- allogeneic natural killer cells
- atezolizumab
- avelumab
- urea
- sorafenib
- irinotecan
- fluzoparib
- paclitaxel
- lapatinib
- hlx07
- cyanocobalamin
- nivolumab
- pembrolizumab
- forrad
- pazopanib
- pemetrexed
- bevacizumab
- cetuximab
- autologous dendritic cells
- vorinostat
- capecitabine
- zoledronic acid
- recombinant epstein-barr virus vaccine
- adebrelimab
- gentamicin
- docetaxel
- lobaplatin
- +15 more
Phase 1 trials (20)
- 7-hydroxystaurosporine
- alvespimycin
- anti cd45 monoclonal antibody
- autologous ebv specific cytotoxic t lymphocytes
- ebv-lmp-2
- tacrolimus
- photochlor
- hydroxyurea
- buparlisib
- methylene blue
- everolimus
- incb062079
- mva
- mva-ebna1/lmp2 vaccine
- nelfinavir
- cd137l-dc-ebv-vax
- tak-500
- BL-B01D1
- p-muc1c-allo1 car-t cells
- u87 autologous car t-cell
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (34)
- Axcan
- AstraZeneca
- Pfizer
- BeOne Medicines
- Biotech Pharmaceutical Co., Ltd.
- Cancer Prevention Pharmaceuticals, Inc.
- Innovent Biologics (Suzhou) Co. Ltd.
- OptiNose AS
- Pari Pharma GmbH
- University of London
- China Three Gorges University, Yichang, China
- Guangzhou Medical University
- Hong Kong Nasopharyngeal Cancer Study Group Limited
- Osaka University
- Pierre and Marie Curie University
- Radboud University
- University of Hamburg
- University of Michigan
- University of Rochester
- University of Bologna
- Capital Medical University
- Chinese University of Hong Kong
- Xiamen University
- The University of Hong Kong
- SLA Pharma
- University of Paris
- University of Sherbrooke
- Johannes Gutenburg University
- Dutch Cancer Society
- Wuzhou Red Cross Hospital
- +4 more
Organization Involved with Phase 2 Indications (54)
- Celgene
- Roche
- Eli Lilly
- Sanofi
- Novartis
- Allakos, Inc.
- Atara Biotherapeutics
- Cancer Insight, LLC
- Hengrui Therapeutics, Inc.
- Sponsor GmbH
- China International Medical Foundation
- National Cancer Institute (NCI)
- Central South University
- Cornell University
- Dokuz Eylul University
- Eastern Cooperative Oncology Group
- First People's Hospital of Foshan
- Guangxi Medical University
- King Faisal University
- Johns Hopkins University
- Norwegian University of Science and Technology
- Ohio State University
- Providence Hospital
- Radiation Therapy Oncology Group
- Southwest Oncology Group
- Stanford University
- The Wistar Institute
- University of Milan
- University of South Florida
- University of Toronto
- +24 more
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (5)